Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
MINERVA NEUROSCIENCES INC (NERV) Stock Price & Overview
NASDAQ:NERV • US6033802058
Current stock price
6.59 USD
+0.2 (+3.13%)
Last:
The current stock price of NERV is 6.59 USD. Today NERV is up by 3.13%. In the past month the price increased by 6.06%. In the past year, price increased by 275.88%.
NERV Key Statistics
52-Week Range1.3 - 12.46
Current NERV stock price positioned within its 52-week range.
1-Month Range5.02 - 7.58
Current NERV stock price positioned within its 1-month range.
- Market Cap
- 285.149M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.32
- Dividend Yield
- N/A
NERV Stock Performance
Today
+3.13%
1 Week
-13.06%
1 Month
+6.06%
3 Months
+57.39%
Longer-term
6 Months +52.14%
1 Year +275.88%
2 Years +170.77%
3 Years +128.21%
5 Years -66.44%
10 Years -87.58%
NERV Stock Chart
NERV Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NERV. When comparing the yearly performance of all stocks, NERV is one of the better performing stocks in the market, outperforming 98.25% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NERV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NERV. The financial health of NERV is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NERV Earnings
Next Earnings DateMay 6, 2026
Last Earnings DateMar 11, 2026
PeriodQ4 / 2025
EPS Reported-$0.64
Revenue Reported
EPS Surprise -109.15%
Revenue Surprise %
NERV Forecast & Estimates
7 analysts have analysed NERV and the average price target is 7.4 USD. This implies a price increase of 12.22% is expected in the next year compared to the current price of 6.59.
Analysts
Analysts45.71
Price Target7.4 (12.29%)
EPS Next Y51.15%
Revenue Next YearN/A
NERV Financial Highlights
Over the last trailing twelve months NERV reported a non-GAAP Earnings per Share(EPS) of -3.32. The EPS increased by 31.55% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-293.42M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -299.51% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%-14.29%
Sales Q2Q%N/A
EPS 1Y (TTM)31.55%
Revenue 1Y (TTM)N/A
NERV Ownership
Ownership
Inst Owners68.19%
Shares43.27M
Float41.72M
Ins Owners0.65%
Short Float %2.77%
Short Ratio4.09
NERV Industry Overview
NERV operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.6
- Average Fwd P/E
- 22.2
- Average Debt/Equity
- 2.2
NERV Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.97 | 360.632B | ||
| AMGN | AMGEN INC | 15.23 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.78 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.17 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.7 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.66 | 25.03B | ||
| INCY | INCYTE CORP | 10.78 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NERV
Company Profile
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Company Info
IPO: 2014-06-25
MINERVA NEUROSCIENCES INC
1601 Trapelo Road, Suite 284
Waltham MASSACHUSETTS 02451 US
CEO: Remy Luthringer
Employees: 7
Phone: 16176007373
MINERVA NEUROSCIENCES INC / NERV FAQ
Can you describe the business of MINERVA NEUROSCIENCES INC?
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
What is the stock price of MINERVA NEUROSCIENCES INC today?
The current stock price of NERV is 6.59 USD. The price increased by 3.13% in the last trading session.
Does NERV stock pay dividends?
NERV does not pay a dividend.
How is the ChartMill rating for MINERVA NEUROSCIENCES INC?
NERV has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the ex-dividend date for NERV stock?
The next ex-dividend date for MINERVA NEUROSCIENCES INC (NERV) is November 3, 2022.
Can you provide the market cap for MINERVA NEUROSCIENCES INC?
MINERVA NEUROSCIENCES INC (NERV) has a market capitalization of 285.15M USD. This makes NERV a Micro Cap stock.
What is the next earnings date for NERV stock?
MINERVA NEUROSCIENCES INC (NERV) will report earnings on 2026-05-06.